[Thymosin alpha 1 for the adjuvant treatment of coronavirus disease 2019: a retrospective cohort study].

Wang T, Lin Q, Xie Y, Yang L, Cao S, Dong H, Du J, Wang R

Zhonghua wei zhong bing ji jiu yi xue1 May 2022Cited by 4 (Europe PMC)

PMID35728851DOI10.3760/cma.j.cn121430-20211013-01478PepBankPUB-35728851

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In patients with COVID-19, crude 28-day deaths were 35.5% in the thymosin group and 28.1% in the non-thymosin group before adjustment.
In plain wordsIn patients with COVID-19, 35.5% of those given thymosin alpha‑1 and 28.1% of those not given it died within 28 days, before adjustment.
Peptide
Thymosin alpha-1
Outcome
Increase28-day deaths, crude counts
Study
n = 95
Comparator
No thymosin alpha 1
Analysis
Primary
Outcome group
Mortality · Infection
Studied dose
Dose not stated
Measurements
28-day deaths
35.5%
thymosin group
28-day deaths
28.1%
non-thymosin group
Source sentences
Summary
Among the 95 patients, there were 31 cases in thymosin group and 64 cases in non-thymosin group; 29 patients died 28 days after admission, including 11 cases (35.5%) in thymosin group and 18 cases (28.1%) in non-thymosin group.
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed to collect clinical data of 95 patients treated by Shanghai Aid Medical Team in Wuhan Third Hospital during January 31, 2020 and March 4, 2020, who were confirmed COVID-19.
Summary · context
They were divided into two groups according to whether they were treated with thymosin alpha 1 after admission.
Report a problemFND-3572885101
02HumanObservational studyEfficacy outcome
In patients with COVID-19, the Kaplan-Meier curve showed better 28-day survival with thymosin alpha‑1.
In plain wordsIn patients with COVID-19, the survival curve showed better 28-day survival with thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
Increase28-day survival, Kaplan-Meier curve
Study
n = 95
Comparator
No thymosin alpha 1
Analysis
Primary
Outcome group
Mortality · Infection
Studied dose
Dose not stated
Source sentences
Summary
Kaplan-Meier survival curve showed that thymosin alpha 1 could improve the 28-day survival of patients with COVID-19
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed to collect clinical data of 95 patients treated by Shanghai Aid Medical Team in Wuhan Third Hospital during January 31, 2020 and March 4, 2020, who were confirmed COVID-19.
Summary · context
They were divided into two groups according to whether they were treated with thymosin alpha 1 after admission.
Report a problemFND-3572885102
03HumanObservational studyEfficacy outcome
In patients with COVID-19, thymosin alpha‑1 did not significantly change 28-day mortality in the univariate Cox model.
In plain wordsIn patients with COVID-19, a simple unadjusted analysis found no clear difference in 28-day deaths with thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
No significant change28-day mortality, univariate Cox model
Study
n = 95
Comparator
No thymosin alpha 1
Analysis
Primary
Outcome group
Mortality · Infection
Studied dose
Dose not stated
Measurements
HR
0.48 ratio
univariate Cox
95% CI
0.2 to 1.14
univariate Cox
Source sentences
Summary
but the univariate Cox model analysis showed that the difference was not statistically significant [hazard ratio (HR) = 0.48, 95% confidence interval (95%CI) was 0.20-1.14, P = 0.098]
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed to collect clinical data of 95 patients treated by Shanghai Aid Medical Team in Wuhan Third Hospital during January 31, 2020 and March 4, 2020, who were confirmed COVID-19.
Summary · context
They were divided into two groups according to whether they were treated with thymosin alpha 1 after admission.
Report a problemFND-3572885103
04HumanObservational studyEfficacy outcome
In patients with COVID-19, thymosin alpha‑1 was linked to lower 28-day mortality in the multivariate Cox model.
In plain wordsIn patients with COVID-19, thymosin alpha‑1 was linked to fewer deaths within 28 days after adjustment for other factors.
Peptide
Thymosin alpha-1
Outcome
Decrease28-day mortality, multivariate Cox model
Study
n = 95
Comparator
No thymosin alpha 1
Analysis
Primary
Outcome group
Mortality · Infection
Studied dose
Dose not stated
Measurements
HR
0.15 ratio
multivariate Cox
95% CI
0.04 to 0.55
multivariate Cox
Source sentences
Summary
multivariate Cox model analysis showed that thymosin alpha 1 was the factor to improve the 28-day mortality (HR = 0.15, 95%CI was 0.04-0.55, P = 0.004)
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed to collect clinical data of 95 patients treated by Shanghai Aid Medical Team in Wuhan Third Hospital during January 31, 2020 and March 4, 2020, who were confirmed COVID-19.
Summary · context
They were divided into two groups according to whether they were treated with thymosin alpha 1 after admission.
Report a problemFND-3572885104
05HumanObservational studyEfficacy outcome
In patients with COVID-19, thymosin alpha‑1 was linked to lower 28-day mortality in the weighted multivariate Cox model after adjustment.
In plain wordsIn patients with COVID-19, thymosin alpha‑1 was linked to better 28-day survival after adjustment for age, sex and other factors.
Peptide
Thymosin alpha-1
Outcome
Decrease28-day mortality (hazard of death), weighted multivariate Cox model
Study
n = 95
Comparator
No thymosin alpha 1
Analysis
Primary
Outcome group
Mortality · Infection
Studied dose
Dose not stated
Measurements
HR
0.45 ratio
weighted multivariate Cox
95% CI
0.25 to 0.84
weighted multivariate Cox
Source sentences
Summary
After adjustment for age, gender, LYM and other factors, weighted multivariate Cox analysis model showed thymosin alpha 1 could significantly improve the 28-day survival of COVID-19 patients (HR = 0.45, 95%CI was 0.25-0.84, P = 0.012).
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed to collect clinical data of 95 patients treated by Shanghai Aid Medical Team in Wuhan Third Hospital during January 31, 2020 and March 4, 2020, who were confirmed COVID-19.
Summary · context
They were divided into two groups according to whether they were treated with thymosin alpha 1 after admission.
Report a problemFND-3572885105
06HumanObservational studyEfficacy outcome
In patients with COVID-19, days without a ventilator at 28 days did not differ significantly between the thymosin and non-thymosin groups.
In plain wordsIn patients with COVID-19, days without a ventilator did not differ between those given thymosin alpha‑1 and those not given it.
Peptide
Thymosin alpha-1
Outcome
No significant changeVentilator-free days at 28 days
Study
n = 95
Comparator
No thymosin alpha 1
Analysis
Secondary
Outcome group
Respiratory function · Respiratory
Studied dose
Dose not stated
Source sentences
Summary
In terms of secondary outcomes, no statistical difference (all P > 0.05) was found between two groups in days without ventilator at 28 days after admission (days: 17.97±13.56 vs. 20.09±12.67) and the increase of LYM at 7 days after admission [×10⁹/L: -0.07 (-0.23, 0.43) vs. 0.12 (-0.54, 0.41)].
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed to collect clinical data of 95 patients treated by Shanghai Aid Medical Team in Wuhan Third Hospital during January 31, 2020 and March 4, 2020, who were confirmed COVID-19.
Summary · context
They were divided into two groups according to whether they were treated with thymosin alpha 1 after admission.
Report a problemFND-3572885106
07HumanObservational studyEfficacy outcome
In patients with COVID-19, the 7-day increase in lymphocyte count did not differ significantly between the thymosin and non-thymosin groups.
In plain wordsIn patients with COVID-19, the rise in lymphocyte count after 7 days did not differ with or without thymosin alpha‑1.
Peptide
Thymosin alpha-1
Outcome
No significant changeLymphocyte count increase at 7 days
Study
n = 95
Comparator
No thymosin alpha 1
Analysis
Secondary
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In terms of secondary outcomes, no statistical difference (all P > 0.05) was found between two groups in days without ventilator at 28 days after admission (days: 17.97±13.56 vs. 20.09±12.67) and the increase of LYM at 7 days after admission [×10⁹/L: -0.07 (-0.23, 0.43) vs. 0.12 (-0.54, 0.41)].
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed to collect clinical data of 95 patients treated by Shanghai Aid Medical Team in Wuhan Third Hospital during January 31, 2020 and March 4, 2020, who were confirmed COVID-19.
Summary · context
They were divided into two groups according to whether they were treated with thymosin alpha 1 after admission.
Report a problemFND-3572885107
08HumanObservational studyEfficacy outcome
In patients with COVID-19, the 7-day decrease in CRP was significantly greater in the thymosin group than in the non-thymosin group.
In plain wordsIn patients with COVID-19, CRP fell more after 7 days in those given thymosin alpha‑1 than in those not given it.
Peptide
Thymosin alpha-1
Outcome
DecreaseC-reactive protein decrease at 7 days
Study
n = 95
Comparator
No thymosin alpha 1
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
But the decrease of CRP at 7 days after admission in thymosin alpha group was significantly greater than that in non-thymosin group [mg/L: 39.99 (8.44, 82.22) vs. 0.53 (-7.78, 22.93), P < 0.05].
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort study was performed to collect clinical data of 95 patients treated by Shanghai Aid Medical Team in Wuhan Third Hospital during January 31, 2020 and March 4, 2020, who were confirmed COVID-19.
Summary · context
They were divided into two groups according to whether they were treated with thymosin alpha 1 after admission.
Report a problemFND-3572885108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.